相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME
Subodh Verma et al.
CIRCULATION (2018)
Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial
Silvio E. Inzucchi et al.
DIABETES CARE (2018)
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
Antonius Baartscheer et al.
DIABETOLOGIA (2017)
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?
Xingjuan Shi et al.
MOLECULAR AND CELLULAR BIOCHEMISTRY (2017)
Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial
David Z. I. Cherney et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
The Metabolodiuretic Promise of Sodium-Dependent Glucose Cotransporter 2 Inhibition The Search for the Sweet Spot in Heart Failure
Subodh Verma et al.
JAMA CARDIOLOGY (2017)
Revascularization for patients with diabetes mellitus and stable ischemic heart disease: an update
G. B. John Mancini et al.
CURRENT OPINION IN CARDIOLOGY (2017)
Pharmacologic Management of Type 2 Diabetes: 2016 Interim Update Canadian Diabetes Association Clinical Practice Guidelines Expert Committee
Gillian Booth et al.
CANADIAN JOURNAL OF DIABETES (2016)
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D. Lopaschuk et al.
CELL METABOLISM (2016)
Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications
Hiddo J. L. Heerspink et al.
CIRCULATION (2016)
Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Pharmacodynamic Effects of Single and Multiple Doses of Empagliflozin in Patients With Type 2 Diabetes
Tim Heise et al.
CLINICAL THERAPEUTICS (2016)
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?
Subodh Verma et al.
DIABETES CARE (2016)
8. Pharmacologic Approaches to Glycemic Treatment
DIABETES CARE (2016)
SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?
Naveed Sattar et al.
DIABETOLOGIA (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
David Fitchett et al.
EUROPEAN HEART JOURNAL (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Secondary Prevention After Coronary Artery Bypass Graft Surgery A Scientific Statement From the American Heart Association
Alexander Kulik et al.
CIRCULATION (2015)
Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes
Petar M. Seferovic et al.
EUROPEAN HEART JOURNAL (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Lars Ryden et al.
EUROPEAN HEART JOURNAL (2013)
Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial
Arie Pieter Kappetein et al.
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY (2013)
Incidence and trends of heart failure admissions after coronary artery bypass grafting surgery
Abel E. Moreyra et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Comparison of coronary artery bypass surgery and percutaneous coronary intervention in patients with diabetes: a meta-analysis of randomised controlled trials
Subodh Verma et al.
LANCET DIABETES & ENDOCRINOLOGY (2013)
Differences in Prevalence, Extent, Severity, and Prognosis of Coronary Artery Disease Among Patients With and Without Diabetes Undergoing Coronary Computed Tomography Angiography Results from 10,110 individuals from the CONFIRM (COronary CT Angiography EvaluatioN For Clinical Outcomes): an InteRnational Multicenter Registry
Jamal S. Rana et al.
DIABETES CARE (2012)
Strategies for Multivessel Revascularization in Patients with Diabetes
Michael E. Farkouh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery
Jean L. Rouleau et al.
CIRCULATION (2008)
Cardiac medical therapy in patients after undergoing coronary artery bypass graft surgery - A review of randomized controlled trials
K Okrainec et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
New diagnostic criteria for diabetes and coronary artery disease:: Insights from an angiographic study
F Ledru et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2001)
分享论文
